arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Turn Therapeutics Inc.

TTRX

$10.54 ▲ +0.84 (+8.66%) at close

7 Visible periods

20 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Turn Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $310.7M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -7.4% ↗

FCF / Share $-0.06

Trailing P/E —

Price / Book 51.3x

FCF Yield —

Debt / Equity 1.19

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-970.97K

↓ -195.5% —

FCF / Share Free cash flow per share

$-0.06

↓ -401.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
EPS Growth YoY (%)	-200.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	-133.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-195.5% Weak Weak Year-over-year change in net income	N/M	-185.7% Weak Weak Year-over-year change in net income	—	—	—	—
FCF Growth YoY (%)	-401.0% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
FCF / Net Income (x)	1.68x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	-4.21x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	—	0.91x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.33x Good Good Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Return on Invested Capital (%)	-7.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-37.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-299.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-37.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	146.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	128.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-6.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-18.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-44.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	-16.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-15.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-206%)	6.0% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-60%)	—	-40.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-368%)	182.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1114%)	160.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+972%)	—

⚖️ Is the balance sheet risky? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Debt to Equity (x)	1.19x Caution Caution Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+98%)	—	—	—	—	—	—
Net Debt (USD)	$-3.75M	$-4.03M	$-513.70K	—	$-498.29K	$-498.29K	—
Debt / EBITDA (x)	-5.83x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Basic EPS, GAAP (USD)	$-0.03	$0.01	$-0.07	$-0.01	$-0.02	$-0.03	—
Free Cash Flow per Share (USD)	$-0.06	—	—	$-0.01	—	—	—
Book Value per Share (USD)	$0.21	$0.16	$0.02	$0.03	$-0.01	$-0.02	—
Tangible Book Value per Share (USD)	$0.17	$0.13	$-0.01	$0.03	$-0.04	$-0.02	—
Basic Weighted Avg Shares (shares)	29.48M	—	27.98M	26.96M	—	26.65M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Working Capital (USD)	$6.32M	$-806.98K	$985.49K	—	$389.99K	—	—
LT Debt (USD)	$7.26M	—	—	—	—	—	—
Total Equity (USD)	$6.12M	$4.69M	$504.02K	$818.71K	$-177.43K	$-414.30K	$85.77K

📋 What is driving earnings? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Net Income, GAAP (USD)	$-970.97K	$279.07K	$-1.90M	$-328.55K	$-323.13K	$-666.44K	—
Operating Cash Flow (USD)	$-1.63M	$-1.18M	—	$-298.06K	$-430.55K	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 3 years · 7 quarters

Turn Therapeutics Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare TTRX with peers